Nanotherapeutics delivering protease inhibitors and cytostatics for advanced treatment strategy of chemorefractory Head and Neck carcinomas
PROJECT OBJECTIVES:
The project is dedicated to developing polymeric nanotherapeutics for treating head and neck carcinoma, as wells as other types of cancer that demonstrate multidrug resistance or low sensitivity to chemotherapy. The project is conducted in collaboration with the Institute of Macromolecular Chemistry of the CAS and Motol hospital. Our laboratory is involved in evaluating the antitumor activity of the developed nanotherapeutics in vitro and in vivo.
| Project number | NU21-03-00273 |
| Beneficiary | Institute of Macromolecular Chemistry of the CAS; Institute of Microbiology of the CAS |
| Principal investigator | RNDr. Chytil Petr, Ph.D.; RNDr. Marek Kovář, Ph.D. |
| Funding Provider | AZV ČR |
| Start of the project | 2021 |
| End of the project | 2024 |
National Institute for Cancer Research (NICR)
Project objectives:
The main objective of the project is to establish and build the National Institute for Cancer Research (NICR) as a new national scientific authority in the field of cancer research. The NICR will enable the creation of a nationwide network of collaborating institutions conducting cutting-edge cancer research. Oncology research is currently not sufficiently coordinated and is fragmented across institutions that do not collaborate and do not use the available research infrastructure efficiently and effectively enough. The thematic and especially infrastructural complementarity of individual departments within the NICR will make it possible to remedy this situation and thus achieve the complexity of approach that is essential for modern oncology research. Cancer research will become much more coordinated, strategic and efficient at the national level through the creation of the NICR, which will increase its quality and thus its international competence.
EXCELES projects are funded by a grant from the Ministry of Education, Youth and Sports under the EXCELES programme, which aims to support excellent research in priority areas of public interest in the health sector. The EXCELES programme is funded by the European Union through the Recovery and Resilience Facility (RRF) – NextGeneretionEU.
| Project number | LX22NPO5102 |
| Beneficiary | Charles University |
| Principal investigator | prof. MUDr. Aleksi Šedo, DrSc. |
| Start of the project | 06/2022 |
| End of the project | 12/2025 |
| Number of co-beneficiaries (coinvestigators) | 11, IMIC is a co-beneficiary (coinvestigator) |
| Coinvestigator for IMIC | RNDr. Marek Kovář, Ph.D. |
Complexes of IL-2 and anti-IL-2 mAb with selective stimulatory activity for CD25+ T cells in cancer immunotherapy: changing the paradigm
project objectives:
The project is dedicated to researching cytokine IL-2 and IL-2 monoclonal antibody complexes (IL-2/anti-IL-2 mAb complexes) that exhibit strong and selective stimulatory activity for cells expressing the IL-2 receptor subunit CD25. The study focuses on evaluating the potential of combining aforementioned immunocomplexes or recombinant fusion (chimeric) immunocytokines, which mimick such complexes both structurally and functionally, with immune checkpoint inhibitors for cancer immunotherapy.
| Project number | GA22-20548S |
| Beneficiary | Institute of Microbiology of the CAS |
| Principal investigator | RNDr. Marek Kovář, Ph.D. |
| Funding Provider | GA ČR |
| Start of the project | 2022 |
| End of the project | 2025 |
